DK2401272T3 - Amorf salt af en makrocyklisk inhibitor af hcv - Google Patents
Amorf salt af en makrocyklisk inhibitor af hcv Download PDFInfo
- Publication number
- DK2401272T3 DK2401272T3 DK10706539.3T DK10706539T DK2401272T3 DK 2401272 T3 DK2401272 T3 DK 2401272T3 DK 10706539 T DK10706539 T DK 10706539T DK 2401272 T3 DK2401272 T3 DK 2401272T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- hcv
- formula
- amorphous
- sodium salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Natriumsalt af forbindelsen med formel I:
(0 i fast amorf form.
2. Fremgangsmåde til fremstilling af saltet ifølge krav 1, der omfatter: (a) fremstilling af en blanding af forbindelsen med formel I i et ikke-vandigt opløsningsmiddel og en vandig natriumhydroxid; og (b) sprøjtetørring af blandingen fra (a) i et sprøj tetørringsapparat.
3. Fremgangsmåde ifølge krav 2, hvor trin a) omfatter blanding af en natriumhydroxidopløsning i vand med opløsningsmidlet og efterfølgende tilsætning af forbindelsen med formel I.
4. Fremgangsmåde ifølge krav 3, hvor i trin a) forbindelsen med formel I får mulighed for at danne en opløsning.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 4, hvor opløsningsmidlet er et halogeneret carbonhydrid.
6. Fremgangsmåde ifølge krav 2, hvor opløsningsmidlet er dichlormethan, og den vandige natriumhydroxid er fra ca. 7,5 N til ca. 12,5 N natriumhydroxidopløsning i vand.
7. Farmaceutisk sammensætning, der omfatter natriumsaltet af forbindelsen med formel I i amorf form ifølge krav 1 og et farmaceutisk acceptabelt bæremateriale.
8. Forbindelse ifølge krav 1 til anvendelse som en medicin.
9. Forbindelse ifølge krav 1 til anvendelse som en HCV- inhibitor.
10. Anvendelse af forbindelsen ifølge krav 1 til fremstilling af et medikament til behandling af HCV.
11. Kombination, der omfatter: (a) forbindelsen ifølge krav 1; og (b) en anden antiviral forbindelse som et kombineret præparat til samtidig, separat eller sekventiel anvendelse.
12. Kombination ifølge krav 11, hvor den antivirale forbindelse er en anti-HCV-forbindelse.
13. Kombination ifølge krav 12, hvor anti-HCV-forbindelsen er en inhibitor af HCV-polymerase, en inhibitor af HCV-protease, en inhibitor af andre mål i HCV-livscyklen, et immunmodulatorisk middel eller en kombination deraf.
14. Kombination, der omfatter: (a) forbindelsen ifølge krav 1; og (b) ritonavir som et kombineret præparat til samtidig, separat eller sekventiel anvendelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09153964 | 2009-02-27 | ||
| PCT/EP2010/001197 WO2010097229A2 (en) | 2009-02-27 | 2010-02-26 | Amorphous salt of a macrocyclic inhibitor of hcv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2401272T3 true DK2401272T3 (da) | 2017-02-27 |
Family
ID=40756982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10706539.3T DK2401272T3 (da) | 2009-02-27 | 2010-02-26 | Amorf salt af en makrocyklisk inhibitor af hcv |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9321758B2 (da) |
| EP (2) | EP3150596A1 (da) |
| JP (2) | JP5711672B2 (da) |
| KR (2) | KR101868412B1 (da) |
| CN (2) | CN104478868A (da) |
| AU (1) | AU2010219160B2 (da) |
| BR (1) | BRPI1008918A2 (da) |
| CA (2) | CA2898529C (da) |
| CY (1) | CY1119121T1 (da) |
| DK (1) | DK2401272T3 (da) |
| ES (1) | ES2616603T3 (da) |
| HK (2) | HK1166315A1 (da) |
| HR (1) | HRP20170214T1 (da) |
| HU (1) | HUE031738T2 (da) |
| IL (2) | IL214398A0 (da) |
| LT (1) | LT2401272T (da) |
| MX (1) | MX340792B (da) |
| NZ (1) | NZ594403A (da) |
| PL (1) | PL2401272T3 (da) |
| PT (1) | PT2401272T (da) |
| RU (1) | RU2536868C2 (da) |
| SG (2) | SG2014008981A (da) |
| SI (1) | SI2401272T1 (da) |
| SM (1) | SMT201700121B (da) |
| WO (1) | WO2010097229A2 (da) |
| ZA (1) | ZA201106303B (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| RU2536868C2 (ru) * | 2009-02-27 | 2014-12-27 | Орто-Макнейл-Янссен Фармасьютикалз Инк | Аморфная соль макроциклического ингибитора hcv |
| EP2907505A3 (en) * | 2011-12-29 | 2015-12-30 | Abbvie Inc. | Solid compositions comprising an HCV inhibitor |
| US9034832B2 (en) * | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| CN104780921A (zh) * | 2012-08-31 | 2015-07-15 | 杨森制药公司 | Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合 |
| US20140212491A1 (en) | 2013-01-31 | 2014-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| AU2014233705C1 (en) * | 2013-03-15 | 2019-10-10 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of HCV inhibitor in the amorphous state |
| EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| CN104995189B (zh) * | 2014-01-21 | 2017-03-29 | 杭州普晒医药科技有限公司 | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 |
| WO2015180253A1 (zh) * | 2014-05-29 | 2015-12-03 | 杭州普晒医药科技有限公司 | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 |
| WO2016054240A1 (en) * | 2014-09-30 | 2016-04-07 | Sean Dalziel | Fixed dose combinations for the treatment of viral diseases |
| CZ2015220A3 (cs) * | 2015-03-27 | 2016-10-05 | Zentiva, K.S. | Amorfní sůl makrocyklického inhibitoru viru hepatitidy C |
| WO2016177625A1 (en) | 2015-05-04 | 2016-11-10 | Sandoz Ag | Amorphous simeprevir potassium |
| WO2017017604A1 (en) | 2015-07-27 | 2017-02-02 | Lupin Limited | Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060083784A1 (en) * | 2002-08-07 | 2006-04-20 | Smithkline Beecham Corporation | Amorphous pharmaceutical compositions |
| SI1680137T1 (sl) * | 2003-10-14 | 2013-02-28 | F. Hoffmann-La Roche Ltd. | Makrocikliäśna karboksilna kislina in acilsulfonamidna spojina kot inhibitor replikacije hcv |
| DK1713823T3 (da) | 2004-01-30 | 2010-03-08 | Medivir Ab | HCV NS-3 serinproteaseinhibitorer |
| US20070249660A1 (en) * | 2004-02-24 | 2007-10-25 | Weber Beat T | Pharmacologically Acceptable Salts of Clopidogrel |
| UA91677C2 (ru) * | 2004-03-30 | 2010-08-25 | Интермюн, Инк. | Макроциклические соединения как ингибиторы вирусной репликации |
| WO2005095403A2 (en) | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| EP1831171A4 (en) * | 2004-11-19 | 2010-09-15 | Matrix Lab Ltd | PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| JP2008115173A (ja) * | 2006-10-13 | 2008-05-22 | Eisai R & D Management Co Ltd | スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体 |
| WO2008073195A2 (en) | 2006-11-08 | 2008-06-19 | Duke University | Method for activation of oxazaphosphorines |
| CN104230918B (zh) * | 2007-02-01 | 2018-01-26 | 爱尔兰詹森科学公司 | Hcv巨环抑制剂的多晶形 |
| EP2121674B1 (en) * | 2007-02-01 | 2010-05-12 | Tibotec Pharmaceuticals | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
| MX2010002300A (es) | 2007-08-29 | 2010-03-18 | Pfizer Prod Inc | Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos. |
| RU2536868C2 (ru) * | 2009-02-27 | 2014-12-27 | Орто-Макнейл-Янссен Фармасьютикалз Инк | Аморфная соль макроциклического ингибитора hcv |
-
2010
- 2010-02-26 RU RU2011139325/04A patent/RU2536868C2/ru not_active IP Right Cessation
- 2010-02-26 NZ NZ594403A patent/NZ594403A/xx not_active IP Right Cessation
- 2010-02-26 CA CA2898529A patent/CA2898529C/en not_active Expired - Fee Related
- 2010-02-26 PT PT107065393T patent/PT2401272T/pt unknown
- 2010-02-26 BR BRPI1008918A patent/BRPI1008918A2/pt not_active Application Discontinuation
- 2010-02-26 CN CN201410616884.3A patent/CN104478868A/zh active Pending
- 2010-02-26 JP JP2011551440A patent/JP5711672B2/ja not_active Expired - Fee Related
- 2010-02-26 CN CN201080009908.9A patent/CN102356080B/zh not_active Expired - Fee Related
- 2010-02-26 US US13/202,166 patent/US9321758B2/en not_active Expired - Fee Related
- 2010-02-26 DK DK10706539.3T patent/DK2401272T3/da active
- 2010-02-26 CA CA2753667A patent/CA2753667C/en not_active Expired - Fee Related
- 2010-02-26 WO PCT/EP2010/001197 patent/WO2010097229A2/en active Application Filing
- 2010-02-26 MX MX2011008999A patent/MX340792B/es active IP Right Grant
- 2010-02-26 KR KR1020177005726A patent/KR101868412B1/ko active IP Right Grant
- 2010-02-26 HU HUE10706539A patent/HUE031738T2/en unknown
- 2010-02-26 SG SG2014008981A patent/SG2014008981A/en unknown
- 2010-02-26 KR KR1020117022464A patent/KR101713066B1/ko active IP Right Grant
- 2010-02-26 LT LTEP10706539.3T patent/LT2401272T/lt unknown
- 2010-02-26 ES ES10706539.3T patent/ES2616603T3/es active Active
- 2010-02-26 AU AU2010219160A patent/AU2010219160B2/en not_active Ceased
- 2010-02-26 SG SG2011059862A patent/SG173772A1/en unknown
- 2010-02-26 EP EP16195560.4A patent/EP3150596A1/en not_active Withdrawn
- 2010-02-26 EP EP10706539.3A patent/EP2401272B1/en active Active
- 2010-02-26 SI SI201031402A patent/SI2401272T1/sl unknown
- 2010-02-26 PL PL10706539T patent/PL2401272T3/pl unknown
-
2011
- 2011-08-02 IL IL214398A patent/IL214398A0/en unknown
- 2011-08-26 ZA ZA2011/06303A patent/ZA201106303B/en unknown
-
2012
- 2012-07-16 HK HK12106950.1A patent/HK1166315A1/xx not_active IP Right Cessation
-
2015
- 2015-03-06 JP JP2015044264A patent/JP6214584B2/ja not_active Expired - Fee Related
- 2015-09-21 HK HK15109245.7A patent/HK1208464A1/xx unknown
- 2015-12-22 IL IL243058A patent/IL243058A0/en unknown
-
2016
- 2016-03-08 US US15/063,821 patent/US20160251345A1/en not_active Abandoned
-
2017
- 2017-02-08 HR HRP20170214TT patent/HRP20170214T1/hr unknown
- 2017-02-22 SM SM201700121T patent/SMT201700121B/it unknown
- 2017-02-22 CY CY20171100246T patent/CY1119121T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2401272T3 (da) | Amorf salt af en makrocyklisk inhibitor af hcv | |
| US8865756B2 (en) | Inhibitors of HCV NS5A | |
| CA2746004C (en) | Inhibitors of hcv ns5a | |
| US20130296311A1 (en) | Inhibitors of hcv ns5a | |
| JP2016515545A (ja) | Ｈｃｖのｒｎａ−ポリメラーゼｎｓ５ｂのヌクレオシド阻害剤、２−｛［（２ｒ，３ｓ，５ｒ）−５−（４−アミノ−２−オキソ−２ｈ−ピリミジン−１−イル）−３−ヒドロキシ−テトラヒドロ−フラン−２−イルメトキシ］−フェノキシ−ホスホリルアミノ｝−プロピオン酸アルキル、その調製の方法及び使用 | |
| CA2800509A1 (en) | Inhibitors of hcv ns5a | |
| CN102712632A (zh) | 黄病毒科病毒的抑制剂 | |
| WO2011156543A2 (en) | Inhibitors of hcv ns5a protein | |
| US9340539B2 (en) | Hepatitis C inhibitor compounds |